SWISS drugmaker Roche is buying US-based BioImagene for some $100m (£64.5m), making another bolt-on acquisition to cement its dominant position in tissue-based cancer diagnostics.
Diagnostics is gaining more importance in cancer treatment, which is being increasingly
matched to the genetic profile of patients. Roche is the world’s largest maker of cancer drugs.
“As part of the personalised healthcare approach, pathologists are increasingly involved in generating information with high impact treatment decisions,” said Daniel O’Day, chief operating officer at Roche.
BioImagene’s products create high-resolution, digital images from glass microscope
“We view the bolt-on acquisition as a good complement to the existing offering in tissues diagnostics, which is becoming increasingly important and crucial for personalised therapy options,” Kepler Capital Markets analyst Martin Voegtli said.